MLICM
INZY

Metropolitan Life Insurance Company (MetLife)’s Inozyme Pharma INZY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,728
Closed -$20.9K – 1046
2024
Q1 		$20.9K Sell
2,728
-147
-5% -$807 ﹤0.01% 1840
2023
Q4 		$12.2K Buy
2,875
+1,006
+54% +$3.57K ﹤0.01% 2112
2023
Q3 		$7.85K Hold
1,869
– – ﹤0.01% 2319
2023
Q2 		$10.4K Buy
+1,869
New +$11K ﹤0.01% 2282

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s INZY Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 2,728 shares — an estimated $20.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in INZY in Q2 2023 and held it in 4 quarters. The position peaked at $20.9K in Q1 2024. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,728 Inozyme Pharma shares in Q2 2024, an estimated $20.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Inozyme Pharma in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Inozyme Pharma position peaked at $20.9K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.